On Oct 23, major Wall Street analysts update their ratings for $Editas Medicine (EDIT.US)$, with price targets ranging from $7 to $13.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $7.
Wells Fargo analyst Yanan Zhu maintains with a buy rating, and sets the target price at $9.
Baird analyst Jack Allen maintains with a buy rating, and adjusts the target price from $18 to $10.
Oppenheimer analyst Jay Olson maintains with a hold rating, and adjusts the target price from $12 to $10.
Truist Financial analyst Joon Lee maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The decision by Editas Medicine to shift focus to in vivo SCD approach and consider partnerships for reni-cel is seen as a potentially more strategic utilization of its knowledge and resources to generate value, following preclinical successes in in vivo editing of HSPCs.
Editas Medicine has shared preliminary results from its in vivo approach which focuses on using targeted lipid nanoparticle delivery to modify hematopoietic stem cells with the CRISPR-Cas12a enzyme. Simultaneously, the company has expressed an intent to form global partnerships for reni-cel, aiming to concentrate its resources on in vivo programs. Despite the promising early in vivo data, it is anticipated that investors may find it challenging to place significant value on a platform that is at such an early stage of development.
Here are the latest investment ratings and price targets for $Editas Medicine (EDIT.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.